Cited 0 times in
핵의학 치료의 최신지견
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 윤미진 | - |
dc.contributor.author | 이종두 | - |
dc.date.accessioned | 2018-10-29T16:40:08Z | - |
dc.date.available | 2018-10-29T16:40:08Z | - |
dc.date.issued | 2003 | - |
dc.identifier.issn | 1975-8456 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/163844 | - |
dc.description.abstract | Radionuclides are naturally occurring unstable atoms that undergo radioactive decay. There are ways of radioactive decay emitting different types of radiation based on their physical properties. Radiation for medical purposes include gamma rays, characteristic X-rays, negative and positive electrons, and alpha particles. Different from external radiotherapy, radionuclide therapy internally delivers therapeutic doses of radiation to the targeted tissue. Historically, P-32 orthophosphate was used for the management of myeloproliferative disorders. I-131 has been used for the treatment of hyperthyroidism as well as thyroid cancer for decades. It is one of the most commonly used therapeutic radionuclides in the current practice and its usefulness has been well established by selectively ablating thyroid tissue. For bone pain by osteoblastic metastases, phosphorus-32, strontium-89, samarium-153, or rhenium-186 could be effectively used in combination with narcotics. Another well known radionuclide therapy is I-131 MIBG for the palliation of patients with inoperable tumors of neural crest origin. In contrast to systemic administration of radioactive materials, local control of malignant tumors could be done by delivering radiation through an intratumoral or intraarterial route. In addition, radioactive skin patch or stent has a promising role in killing skin cancers, esophageal cancer, or malignant biliary strictures. Recently, I-131 or Y-90 conjugated with monoclonal antibodies increases the efficacy of radiation damage to lymphoma tissue employing the targeting effect of monoclonal antibodies. Likewise, radionuclide therapy in combination with gene therapy seems to be promising albeit tumor specific ways of gene delivery should be further investigated. Other possible candidates in radionuclide therapy are radioactive peptides and antisense oligonuclides. | - |
dc.description.statementOfResponsibility | open | - |
dc.format | application/pdf | - |
dc.language | JOURNAL OF THE KOREAN MEDICAL ASSOCIATION | - |
dc.publisher | JOURNAL OF THE KOREAN MEDICAL ASSOCIATION | - |
dc.relation.isPartOf | JOURNAL OF THE KOREAN MEDICAL ASSOCIATION | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.rights | https://creativecommons.org/licenses/by-nc-nd/2.0/kr/ | - |
dc.title | 핵의학 치료의 최신지견 | - |
dc.title.alternative | Recent Advances in Radionuclide Therapy | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Nuclear Medicine (핵의학교실) | - |
dc.contributor.googleauthor | 윤미진 | - |
dc.contributor.googleauthor | 이종두 | - |
dc.contributor.localId | A02550 | - |
dc.contributor.localId | A03138 | - |
dc.relation.journalcode | J01833 | - |
dc.identifier.eissn | 2093-5951 | - |
dc.subject.keyword | Radionuclide | - |
dc.subject.keyword | Therapy | - |
dc.subject.keyword | Radiation | - |
dc.contributor.alternativeName | Yun, Mi Jin | - |
dc.contributor.alternativeName | Lee, Jong Doo | - |
dc.contributor.affiliatedAuthor | 윤미진 | - |
dc.contributor.affiliatedAuthor | 이종두 | - |
dc.citation.volume | 46 | - |
dc.citation.number | 3 | - |
dc.citation.startPage | 204 | - |
dc.citation.endPage | 209 | - |
dc.identifier.bibliographicCitation | JOURNAL OF THE KOREAN MEDICAL ASSOCIATION, Vol.46(3) : 204-209, 2003 | - |
dc.identifier.rimsid | 60621 | - |
dc.type.rims | ART | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.